⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28166120 | 1.00 | — | — | |
| SCHEMBL28232318 | 0.98 | — | — | |
| SCHEMBL27834073 | 0.94 | — | — | |
| SCHEMBL6631277 | 0.83 | CHRNB2 (0.37) | — | |
| SCHEMBL1420015 | 0.82 | ADRB1 (0.36) | — | |
| SCHEMBL17065181 | 0.81 | — | — | |
| SCHEMBL2304918 | 0.80 | — | — | |
| SCHEMBL17065184 | 0.78 | — | — | |
| SCHEMBL28131799 | 0.73 | — | — | |
| SCHEMBL27604039 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023151697-A1 | METTL3 INHIBITOR AND COMPOSITION, AND APPLICATION OF SAME IN MEDICINE | 四川海思科制药有限公司 | 2023-08-17 | — | — | WO | claimed |
| US-11793817-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| CN-116693551-A | Dihydropyrazole azepine compound, pharmaceutical composition containing same and application of compound in resisting tumor | 浙江大学 | 2023-09-05 | — | — | CN | disclosed |
| WO-2023151697-A1 | METTL3 INHIBITOR AND COMPOSITION, AND APPLICATION OF SAME IN MEDICINE | 四川海思科制药有限公司 | 2023-08-17 | — | — | WO | disclosed |
| CN-114507235-A | Compound capable of degrading BTK kinase, preparation method and pharmaceutical application thereof | 海思科医药集团股份有限公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-114478366-A | Pyridone derivative and application thereof in medicine | 海思科医药集团股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20210353637-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-11-18 | — | — | US | disclosed |
| CN-112812100-A | Compound capable of degrading BTK kinase, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2021-05-18 | — | — | CN | disclosed |
| US-10973832-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| CN-112390785-A | BET family bromodomain inhibitor ring derivative, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2021-02-23 | — | — | CN | disclosed |
| US-20170157139-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| CN-104039321-B | Pharmaceutical compounds | 赫普泰雅治疗有限公司 | 2017-02-22 | — | — | CN | disclosed |
| US-9573929-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-02-21 | — | — | US | disclosed |
| EP-2780015-B1 | MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2017-01-04 | — | — | EP | disclosed |
| US-20160068508-A1 | Muscarinic M1 Receptor Agonists | NXERA PHARMA UK LIMITED (GB) | 2016-03-10 | — | — | US | disclosed |
| US-9187451-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-11-17 | — | — | US | disclosed |
| US-20140329803-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| EP-2780015-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2014-09-24 | — | — | EP | disclosed |
| CN-104039321-A | Pharmaceutical compounds | HEPTARES THERAPEUTICS LTD | 2014-09-10 | — | — | CN | disclosed |
| WO-2013072705-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |